Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration

NCT06495918 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

825

Enrollment

INDUSTRY

Sponsor class

Conditions

Neovascular Age-related Macular Degeneration

Interventions

DRUG: OTX-TKI
DRUG: Aflibercept
DRUG: Aflibercept

Sponsor

Ocular Therapeutix, Inc.

Collaborators

[object Object]
[object Object]